Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.

ABSTRACT: BACKGROUND:The prices of newly approved cancer drugs have risen over the past decades. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases. OBJECTIVES:To evaluate the price per median and mean life year gained among newly approved cancer therapies from 1995 to 2017. METHODS:We collected data on the price (in 2017 USD) per life-year gained among cancer drug-indication pairs approved by the US Food and Drug Administration (FDA) between 1995 and 2017. We modeled trends using fractional polynomial and linear spline regression models that controlled for route of administration and cancer type fixed effects. RESULTS:We found that between 1995 and 2012, price increases outstripped median survival gains, a f

SUBMITTER: Chen AJ 

PROVIDER: S-EPMC7589784 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature